Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody ...

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from ...

Add Yahoo as a preferred source to see more of our stories on Google. Merck KGaA will progress its ADC Merck KGaA's antibody-drug conjugate (ADC), precemtabart tocentecan (Precem-TcT), has shown ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate cancer treatment, fuelling the ongoing industry buzz for the promising ...

BETHESDA, Md., Feb. 13, 2026 /PRNewswire/ -- Precision Biologics, Inc. CEO Philip M. Arlen, MD gives a Keynote presentation describing in vitro and in vivo efficacy of its novel tumor-specific ...

Back-to-back Presidential Symposium presentations of ENHERTU from DESTINY-Breast11 and DESTINY-Breast05 demonstrate its potential to become a foundational treatment in curative-intent settings of HER2 ...

Shares of ADC Therapeutics fell after it reported the death of two patients in a late-stage trial for treating an aggressive cancer that starts in white blood cells. The stock fell 7.6% to $4.25 in ...

A new analysis from Komodo Health pinpointed significant disparities by age and insurance in antibody-drug conjugate (ADC) treatment rates for metastatic breast cancer. Age and insurance status were ...